The Effect of Xanthine Oxidase Inhibitor in ChronIc heart failure patients complicaTED with hyper-UricemiA : A (Prospective) Randomized Controlled Clinical Trial of Topiroxostat and Alloprinol
- Conditions
- Hyperuricemia with heart failure
- Registration Number
- JPRN-UMIN000020939
- Lead Sponsor
- Dokkyo Medical University Department of Cardiovascular Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 140
Not provided
Patients who fall into any of the following criteria are excluded from participating in the study. 1.Have a history of hypersensitivity to the test drug 2.Currently on medication of mercaptopurine hydrate or azathioprine 3.Currently have a severe liver failure (AST or ALT level is doubled from the standard values provided by each hospital/clinic) 4.Complicated with chronic liver disease, malignant tumor, active infection, or inflammatory disease 5.Currently have gout arthritis or the disease is cured for less than two weeks 6.Currently have nephrolithiasis or on treatment 7.eGFR is below 30 ml/min/1.73 square meters (CCr 30ml/min) 8.Currently have acute heart failure 9.After acute exacerbation improvement in chronic heart failure is less than two weeks 10. Currently pregnant or possibly conceived a child, or brest feeding 11.Other conditions that physicians judge to be inappropriate to be in the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Rate of change in NT-proBNP from baseline to the 24th week
- Secondary Outcome Measures
Name Time Method